News, lfg! <
News article
BC Capital on Takeaways From Oncolytics' KOL
Call on Pancreatic Cancer, Updated Interim Ph
1/2 GOBLET Study Data
02:08 PM EST, 11/15/2022 (MT Newswires) -- After
attending the KOL webinar on pancreatic cancer
hosted by Oncolytics Biotech pn Monday, and the
strong interim results from the Ph1 /2 GOBLET data,
RBC Capital is "more confident" on the potential
advancement of pelareorep (pela) into a
registrational study and increased likelihood of a
licensing deal. (On the last earnings call,
management said it plans to pursue a single licensing
deal for both the breast cancer and pancreatic cancer
programs.)
Oncolytics hosted a KOL webinar featuring Dirk
Arnold, MD, Ph.D. (Asklepios umorzentrum Hamburg),
Andrea Bullock, MD., MPH (Beth Israel Deaconess
Medical Center) and Thomas Seufferlein, MD., Ph.D.
(Ulm University, Germany) along with the company
management to discuss the current treatment
landscape and unmet medical need in pancreatic
cancer, as well as the updated interim GOBLET study
results which were presented at the SIT annual
meeting. The key opinion leaders provided an
overview of the PAC treatment landscape and
various trials, both successful and those that came up
short, that have guided first and second line
treatment to serve as a foundation for the Goblet
results discussion.
Analyst Douglas Miehm's key takeaways from the KOL